A major breakthrough in targeted therapies for sarcomas is the recent FDA approval of an anti-PDGFRA therapeutic antibody to treat soft tissue sarcomas [56]; which, as we show now for the case of viral sarcomagenesis with KS, are also oncogenically driven by ligand activation of the PDGFRA. Here, PDGFRA is linked to Kaposi's sarcoma.